Patients treated with ponesimod demonstrate reductions in serum neurofilament light chain levels

• Published in: Journal of neurology, neurosurgery and psychiatry Vol. 94; no. Suppl 1; p. A72
• Main Authors: Talbot, Jordan, Kuhle Jens, Ait-Tihyaty, Maria, Singh, Amita, Ibrahim, Turkoz, Saad Ziad, Burcklen Michel, Wong, Janice, Sidorenko Tatiana, Kappos Ludwig
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.11.2023

BackgroundIn the Phase 3 OPTIMUM study (NCT02425644), patients with relapsing multiple sclerosis (RMS) treated with ponesimod (20 mg) had greater reduction in the annualized relapse rate compared with patients treated with teriflunomide (14 mg).ObjectiveTo investigate change from baseline to Week 10...